Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Specifications for biotechnology-derived protein drugs

K B Seamon1

  • 1Immunex Corporation, Seattle, WA 98101-2936, USA. Kseamon@Immunex.com

Current Opinion in Biotechnology
|July 3, 1998
PubMed
Summary

Product specifications ensure human safety and quality, evolving with drug development. Advanced analytical methods enhance regulatory flexibility for biotechnology products.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Irreversible inhibition of forskolin interactions with type I adenylyl cyclase by a 6-isothiocyanate derivative of forskolin.

Molecular pharmacology·1996
Same author

Forskolin carbamates: binding and activation studies with type I adenylyl cyclase.

Journal of medicinal chemistry·1996
Same author

Purification of bovine brain adenylyl cyclase with a novel derivative of forskolin: evidence for a high specific activity form of the enzyme.

Preparative biochemistry & biotechnology·1996
Same author

Regulation of forskolin interactions with type I, II, V, and VI adenylyl cyclases by Gs alpha.

Biochemistry·1994
Same author

Interaction of an estramustine photoaffinity analogue with cytoskeletal proteins in prostate carcinoma cells.

Molecular pharmacology·1994
Same author

Forskolin specifically inhibits the bacterial galactose-H+ transport protein, GalP.

The Journal of biological chemistry·1994

Area of Science:

  • Biotechnology
  • Drug Development
  • Regulatory Science

Background:

  • Product specifications are regulatory and legal standards for human-use products.
  • Specifications adapt throughout drug development, finalized before and sometimes after marketing.
  • Recent regulatory shifts emphasize characterization and final product specifications for biotechnology-derived protein products.

Purpose of the Study:

  • To highlight the importance of characterization and final product specifications for biotechnology-derived protein products.
  • To discuss the role of harmonized guidelines in testing and specifications.
  • To explore how analytical methods influence regulatory flexibility.

Main Methods:

  • Review of regulatory procedures for biotechnology-derived protein products.
  • Analysis of International Conference on Harmonization (ICH) guidelines.
  • Discussion on the impact of analytical method advancements.

Main Results:

  • Characterization and final product specifications are crucial for ensuring the quality of biotechnology products.
  • Harmonized guidelines facilitate standardized testing and specifications.
  • Sensitive, quantitative, and specific analytical methods enable greater regulatory flexibility.

Conclusions:

  • Advanced analytical methods are key to ensuring the quality and regulatory flexibility of biotechnology-derived protein products.
  • Continued refinement of analytical tools will further enhance regulatory flexibility in product development.

Related Experiment Videos